PD-L1 and TIGIT — Drug Target

All drugs that target PD-L1 and TIGIT — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

PD-1/PD-L1 inhibitor and TIGIT inhibitor

Phase 2 pipeline (1)

• Atezolizumab plus Tiraglolumab · Grupo Espanol Multidisciplinario del Cancer Digestivo · PD-1/PD-L1 inhibitor and TIGIT inhibitor · Oncology
  Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.